Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is looking to build its future on research
Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research.
Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd.
Now it plans to put some of that money to work.
'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO.
'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.'
"THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"... more